Table 6.
Cortical Geometry: Anticatabolic Therapies
| Group | Cortical Thickness | Marrow Area | Total Area | Endocortical Perimeter | Periosteal Perimeter | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| VEH: WT/Nmp4−/− | 0.190 ± 0.016/0.184 ± 0.007 | 0.964 ± 0.096/0.958 ± 0.026 | 1.841 ± 0.109/1.834 ± 0.092 | 3.843 ± 0.185/3.861 ± 0.121 | 5.243 ± 0.167/5.242 ± 0.175 | |||||
| ALN: WT/Nmp4−/− | 0.187 ± 0.013/0.181 ± 0.012 | 0.968 ± 0.050/0.963 ± 0.085 | 1.865 ± 0.099/1.836 ± 0.112 | 3.870 ± 0.143/3.874 ± 0.161 | 5.251 ± 0.105/5.204 ± 0.162 | |||||
| ZOL: WT/Nmp4−/− | 0.189 ± 0.010/0.192 ± 0.007 | 1.033 ± 0.091/0.994 ± 0.072 | 1.944 ± 0.080/1.879 ± 0.078 | 4.116 ± 0.183/3.925 ± 0.158 | 5.477 ± 0.170/5.308 ± 0.140 | |||||
| RAL: WT/Nmp4−/− | 0.202 ± 0.010/0.206 ± 0.010 | 0.856 ± 0.076/0.892 ± 0.054 | 1.757 ± 0.063/1.827 ± 0.084 | 3.761 ± 0.123/3.820 ± 0.125 | 5.153 ± 0.098/5.271 ± 0.191 | |||||
| Anticatabolic therapy | G: P = 0.62 | G: P = 0.83 | G: P = 0.72 | G: P = 0.46 | G: P = 0.52 | |||||
| T: P < 0.0001 | T: P < 0.0001 | T: P = 0.0094 | T: P = 0.0010 | T: P = 0.0073 | ||||||
| RAL | A | ZOL | A | ZOL | A | ZOL | A | ZOL | A | |
| ZOL | B | ALN | A | ALN | AB | ALN | B | VEH | B | |
| VEH | B | VEH | A | VEH | AB | VEH | B | ALN | B | |
| ALN | B | RAL | B | RAL | B | RAL | B | RAL | B | |
| GxT: P = 0.92 | GxT: P = 0.58 | GxT: P = 0.25 | GxT: P = 0.12 | GxT: P = 0.10 | ||||||
The micro-CT analyses of the femoral cortical geometry in mice treated with the anticatabolic therapies. The data were analyzed using two-way analyses of variance to compare the anabolic therapies and the anticatabolic monotherapies. Statistical significance was set at P ≤ 0.05, and levels not connected by the same letter are significantly different. The data represent mean ± standard deviation, n = 7 to 12 mice per group.
Abbreviations: G, genotype; T, treatment.